AdvancingHealthThroughInnovation:NewDrugTherapyApprovals2021IMPACTINNOVATIONPREDICTABILITYACCESSFDA’sCenterforDrugEvaluationandResearchJanuary2022TableofContentsDirector’sMessage..............................................................................................................................1ExecutiveSummary.............................................................................................................................2CDER’sNovelDrugApprovalsof2021..................................................................................................5First-in-ClassDrugs....................................................................
发表评论取消回复